| Cas No.: | 724440-27-1 |
| Chemical Name: | 2-[[5-(Benzenesulfonyl)-2-chlorobenzoyl]amino]benzoic acid |
| Synonyms: | BAY8002;2-(2-chloro-5-(phenylsulfonyl)benzamido)benzoic acid;GTPL10405;2-[[5-(benzenesulfonyl)-2-chlorobenzoyl]amino]benzoic acid;BCP30742;BAY 8002;ZB1541;s8747;BAY 8002; BAY8002;2-[[2-Chloro-5-(phenylsulfonyl)benzoyl]amino]benzoic acid;BAY-8002 |
| SMILES: | ClC1C([H])=C([H])C(=C([H])C=1C(N([H])C1=C([H])C([H])=C([H])C([H])=C1C(=O)O[H])=O)S(C1C([H])=C([H])C([H])=C([H])C=1[H])(=O)=O |
| Formula: | C20H14ClNO5S |
| M.Wt: | 415.8469 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity[1]. |
| Target: | IC50: 85 nM (MCT1, in DLD-1 cells)[1] |
| In Vivo: | BAY-8002 (80 and 160 mg/kg, p.o., twice daily, for more than 26 days) significantly inhibits tumor growth in Raji tumor-bearing mice[1]. Animal Model: Female NOD SCID mice bearing Raji cells (7-10 weeks old)[1] Dosage: 80 and 160 mg/kg Administration: P.O. twice daily for more than 26 days Result: Inhibited tumor growth with no obvious body weight loss, but showed no effect on tumor regression. |
| In Vitro: | BAY-8002 is an inhibitor of MCT1, with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4 (IC50 >50 µM in EVSA-T cells)[1]. |
| References: | [1]. Quanz M, et al. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance. Mol Cancer Ther. 2018 Nov;17(11):2285-2296. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|